Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors

PURPOSE: The relapse rate after primary retroperitoneal lymph node dissection (RPLND) for patients with pathologic stage (PS) IIA nonseminomatous germ cell tumors (NSGCTs) is 10%-20% but increases to ≥ 50% for PS IIB disease. We report our experience with 2 cycles of adjuvant etoposide plus cisplati...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: McHugh, Deaglan J., Funt, Samuel A., Silber, Deborah, Knezevic, Andrea, Patil, Sujata, O’Donnell, Devon, Tsai, Stephanie, Reuter, Victor E., Sheinfeld, Joel, Carver, Brett S., Motzer, Robert J., Bajorin, Dean F., Bosl, George J., Feldman, Darren R.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2020
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7164484/
https://ncbi.nlm.nih.gov/pubmed/32109195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02712
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker